Résilience accelerates the roll-out of its medical telemonitoring solution
On January 25, 2022, Résilience announced a series A funding round of €40 million. It was led by Cathay Innovation and strongly supported by Singular. Three European funds also took part in the funding round (Exor, Picus Capital and Seaya Ventures), along with a consortium of health sector stakeholders (MACSF Ventures, Vivalto Ventures, Ramsay Santé and Fondation Santé Service).
Co-founded in 2021 by Céline Lazorthes, Jonathan Benhamou and the Gustave Roussy Institute, the MedTech firm has designed a medical telemonitoring and therapeutic follow-up device.
Wandercraft secures US$45 million for its development in the United States
Wandercraft has announced a series C funding round to secure €45 million from American investment fund Quadrant Management. Bpifrance also took part in the funding round through the PSIM fund. The firm had already completed two funding rounds totaling over US$30 million. Wandercraft has developed an exoskeleton for medical use, aimed at people with reduced mobility. It is targeted primarily at paraplegics and those suffering from myopathy.
HEROIC Santé secures €1 million to improve the day-to-day life of the chronically sick
Lille-based startup HEROIC Santé has raised €1 million from investors and public-sector actors to accelerate its growth. Its objective is to improve the day-to-day life of the chronically sick. The funds should reinforce several priority projects on the comprehensive treatment of endometriosis, the prevention of uterine cancer, a tool to facilitate the everyday life of people with disabilities, the mental health of young people, and type-2 diabetes.
Cureety secures €5 million
Cureety, a startup specialized in data and telemonitoring in oncology has announced a €5 million funding round. The operation coincided with France’s new social security financing law, under which all telemonitoring activities will be reimbursed as of 2022.
Established in March 2018, Cureety aims to optimize patient care, simplify the day-to-day work of caregivers, and improve cancer care through research programs and databases centered on the patient experience.
Zymoptiq secures over €3 million
Established in 2019, the Lille-based biotechnology firm is accelerating the market entry and development of its disruptive enzyme activity measurement technology in France, Europe, and worldwide through a network of commercial partners. It has just concluded a financing round involving – alongside Thia Ventures and Captech Santé – the regional funds Nord Création and Nord France Amorçage, a private investor specialized in the field, and Bpifrance.